Log in to save to my catalogue

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression...

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9e6975b96a954beabd516cbe6928a1f0

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

About this item

Full title

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

Publisher

London, England: SAGE Publications

Journal title

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758835918794623-1758835918794623

Language

English

Formats

Publication information

Publisher

London, England: SAGE Publications

More information

Scope and Contents

Contents

Background:
Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated with imatinib resumption after progression to con...

Alternative Titles

Full title

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_9e6975b96a954beabd516cbe6928a1f0

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9e6975b96a954beabd516cbe6928a1f0

Other Identifiers

ISSN

1758-8359,1758-8340

E-ISSN

1758-8359

DOI

10.1177/1758835918794623

How to access this item